1. Search Result
Search Result
Results for "

FKBP12

" in MedChemExpress (MCE) Product Catalog:

49

Inhibitors & Agonists

4

Natural
Products

2

Recombinant Proteins

3

Isotope-Labeled Compounds

4

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-114421
    FKBP12 PROTAC dTAG-13
    3 Publications Verification

    dTAG-13

    PROTACs FKBP Cancer
    FKBP12 PROTAC dTAG-13 (dTAG-13), a PROTAC-based heterobifunctional degrader, is a selective degrader of FKBP12 F36V with expression of FKBP12F36V in-frame with a protein of interest. FKBP12 PROTAC dTAG-13 effectively engages FKBP12 F36V and CRBN, thereby selectively degrading FKBP12 F36V .
    FKBP12 PROTAC dTAG-13
  • HY-130835

    RC32

    PROTACs FKBP Cancer
    FKBP12 PROTAC RC32 (RC32) is a potent FKBP12 degrader based on PROTAC technology. FKBP12 PROTAC RC32 contains conjugation of Rapamycin (HY-10219) and a ligand for an Cereblon E3 ubiquitin ligase (Pomalidomide; HY-10984) .
    FKBP12 PROTAC RC32
  • HY-123941
    FKBP12 PROTAC dTAG-7
    2 Publications Verification

    dTAG-7

    PROTACs FKBP Epigenetic Reader Domain Cancer
    FKBP12 PROTAC dTAG-7 (dTAG-7) is a heterobifunctional degrader. FKBP12 PROTAC dTAG-7 (dTAG-7) is a degrader of FKBP12 F36V with expression of FKBP12 F36V in-frame with a protein of interest. FKBP12 PROTAC dTAG-7 (dTAG-7) also is a selective degrader of BET bromodomain transcriptional co-activator BRD4 by bridging BET bromodomains to an E3 ubiquitin ligase CRBN .
    FKBP12 PROTAC dTAG-7
  • HY-107452

    PROTAC FKBP12-binding moiety 1

    Ligands for Target Protein for PROTAC FKBP Cancer
    SLF-amido-C2-COOH (PROTAC FKBP12-binding moiety 1) is a synthetic ligand for FKBP (SLF). SLF-amido-C2-COOH (PROTAC FKBP12-binding moiety 1) can be used in the synthesis of PROTACs .
    SLF-amido-C2-COOH
  • HY-153806

    ZZY05-092

    FKBP Cancer
    RapaBlock is a potent, non-immunosuppressive and brain-impermeable FKBP12 ligand .
    RapaBlock
  • HY-103634
    dFKBP-1
    1 Publications Verification

    PROTACs FKBP Cancer
    dFKBP-1 is a potent and PROTAC-based FKBP12 degrader. dFKBP-1 incorporates the ligand SLF (HY-114872) of FKBP12, the Thalidomide based Cereblon ligand and a linker .
    dFKBP-1
  • HY-147098

    PROTACs FKBP Cancer
    dTAG-47, heterobifunctional dTAG molecule, targets mutant FKBP12 (FKBP12 F36V). FKBP12 F36V serves as a degradation tag (dTAG) and is fused to a protein of interest. dTAG-47 can be used for the research of basal-like breast cancers (BBC) .
    dTAG-47
  • HY-170988

    FKBP Ligands for Target Protein for PROTAC Cancer
    FKBP12 ligand-1 is a targeting protein ligand of MC-25B (HY-170983), which is a specific FKBP12 PROTAC .
    FKBP12 ligand-1
  • HY-172266

    Target Protein Ligand-Linker Conjugates Others
    FKBP12 Ligand-Linker Conjugate 2 is a conjugate of the FKBP12 target protein ligand and a linker, and it can be used for the synthesis of FKBP12 PROTAC FM4 (HY-172265) .
    FKBP12 Ligand-Linker Conjugate 2
  • HY-170987

    Target Protein Ligand-Linker Conjugates FKBP Cancer
    FKBP12 Ligand-Linker Conjugate 1 is the conjugate composed of a target protein ligand for FKBP12 and a linker. FKBP12 Ligand-Linker Conjugate 1 can be used for synthesis of PROTAC degrader MC-25B (HY-170983) .
    FKBP12 Ligand-Linker Conjugate 1
  • HY-161794

    FKBP Ligands for Target Protein for PROTAC Cancer
    SP3N is a specific degrader of the prolyl isomerase FKBP12. The alkylamine of SP3N is metabolized to a reactive aldehyde (SP3CHO), which recruits the SCFFBXO22 ligase for FKBP12 degradation. SP3N may be used in research for cancer .
    SP3N
  • HY-145514C
    dTAGV-1 hydrochloride
    1 Publications Verification

    FKBP PROTACs Cancer
    dTAGV-1 hydrochloride is the hydrochloride form of dTAGV-1 that is a small molecule degrader of FKBP12 .
    dTAGV-1 hydrochloride
  • HY-114420
    AP1867-2-(carboxymethoxy)
    1 Publications Verification

    PROTAC FKBP12-binding moiety 2

    FKBP Ligands for Target Protein for PROTAC Cancer
    AP1867-2-(carboxymethoxy), the AP1867 (a synthetic FKBP12 F36V-directed ligand) based moiety, binds to CRBN ligand via a linker to form dTAG molecules .
    AP1867-2-(carboxymethoxy)
  • HY-170986

    Ligands for E3 Ligase Cancer
    E3 ligase Ligand 57 is an E3 ligase ligand of MC-25B (HY-170983) which is a specific FKBP12 PROTAC .
    E3 ligase Ligand 57
  • HY-170983

    FKBP Cancer
    MC-25B is a specific FKBP12 PROTAC degrader. MC-25B degrades FKBP12 with a DC50 of 0.35 μM and a Dmax of 89%. MC-25B facilitates the degradation of nuclear-localized FKBP12 through a DCAF16-dependent mechanism. (Pink: FKBP12 ligand (HY-170988); Blue: E3 ligase ligand HY-170986); Black: linker (HY-128844); FKBP12 ligand+ linker (HY-170987)) .
    MC-25B
  • HY-169148

    PROTACs FKBP Epigenetic Reader Domain Cancer
    YT117R is a PROTAC degrader of FKBP12 and Pink: Target protein ligand: (HY-158301); Black: linker (HY-42776); Blue: E3 ligase ligand (HY-78695)) .
    YT117R
  • HY-173082

    PROTACs FKBP Cancer
    10-SLF is a PROTAC FKBP12 degrader. 10-SLF induces a ternary complex between FKBP12 and FBXW7-R465C, and promotes FBXW7-R465C-dependent proteasomal degradation of FKBP12. 10-SLF selectively reduces FKBP12 levels in cells expressing FBXW7-R465C. Pink: FKBP12 ligand (HY-170988); Black: linker (HY-W004640); Blue: E3 ligase ligand .
    10-SLF
  • HY-134184

    AUTACs Autophagy Inflammation/Immunology Cancer
    AUTAC2 is a FKBP12-targeting autophagy-mediated degrader (AUTAC). AUTAC2 contains an FBnG (p-Fluorobenzyl Guanine) and an SLF (c ligand of FKBP) moiety. SLF binds non-covalently to FKBP12 .
    AUTAC2
  • HY-114872

    Ligands for Target Protein for PROTAC FKBP Cancer
    SLF is a synthetic ligand for FK506-binding protein (FKBP) with an affinity of 3.1 μM for FKBP51 and an IC50 of 2.6 μM for FKBP12. SLF can be used in the synthesis of PROTAC .
    SLF
  • HY-10219
    Rapamycin
    Maximum Cited Publications
    981 Publications Verification

    Sirolimus; AY-22989

    mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial Cancer
    Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .
    Rapamycin
  • HY-131344

    mTOR Autophagy Cancer
    mTOR inhibitor-8 is an mTOR inhibitor and autophagy inducer. mTOR inhibitor-8 inhibits the activity of mTOR via FKBP12 and induces autophagy of A549 human lung cancer cells .
    mTOR inhibitor-8
  • HY-145514
    dTAGV-1 TFA
    1 Publications Verification

    PROTACs Cancer
    dTAGV-1 TFA is a potent and selective degrader of mutant FKBP12 F36V fusion proteins. dTAGV-1 TFA can induce degradation of FKBP12 F36V-Nluc in vivo .
    dTAGV-1 TFA
  • HY-114872A

    Ligands for Target Protein for PROTAC FKBP Cancer
    SLF TFA is a synthetic ligand for FK506-binding protein (FKBP) with an affinity of 3.1 μM for FKBP51 and an IC50 of 2.6 μM for FKBP12. SLF TFA can be used in the synthesis of PROTAC .
    SLF TFA
  • HY-10219S

    Sirolimus-d3; AY-22989-d3

    Isotope-Labeled Compounds mTOR FKBP Autophagy Cancer
    Rapamycin-d3 is the deuterium labeled Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant .
    Rapamycin-d3
  • HY-114434
    AP1867
    3 Publications Verification

    FKBP Cancer
    AP1867 is a synthetic FKBP12 F36V-directed ligand .
    AP1867
  • HY-10219R

    mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial Cancer
    Rapamycin (Standard) is the analytical standard of Rapamycin. This product is intended for research and analytical applications. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .
    Rapamycin (Standard)
  • HY-170998

    Autophagy Inflammation/Immunology
    ATG16L1 stabilizer-1 (compound A3B) is an FKBP12-independent ATG16L1 stabilizer that promotes cellular Autophagy. ATG16L1 stabilizer-1 inhibits ATG16L1 with an EC50 of 12.1 μM in the presence or absence of FKBP12. ATG16L1 stabilizer-1 alone induces GFP-LC3 puncta formation to a small extent with an EC50 of 12.0 μM .
    ATG16L1 stabilizer-1
  • HY-129610

    PROTACs FKBP Cancer
    KB02-SLF is a PROTAC-based nuclear FKBP12 degrader (molecular glue). KB02-SLF promotes nuclear FKBP12 degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems. SLF binds ubiquitin E3 ligase ligand KB02 via a linker to form KB02-SLF .
    KB02-SLF
  • HY-161157

    PROTACs Cancer
    dTAG-13-NEG is a negative control of dTAG-13. dTAG-13 (HY-114421), a PROTAC-based heterobifunctional degrader, is a selective degrader of FKBP12 F36V with expression of FKBP12F36V in-frame with a protein of interest .
    dTAG-13-NEG
  • HY-145514A

    PROTACs FKBP Cancer
    dTAGV-1-NEG is a diastereomer and as a heterobifunctional negative control of dTAGV-1. dTAGV-1 is an FKBP12 F36V-selective degrader .
    dTAGV-1-NEG
  • HY-10218
    Everolimus
    85+ Cited Publications

    RAD001; SDZ-RAD

    mTOR FKBP Autophagy Apoptosis Bacterial Cancer
    Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .
    Everolimus
  • HY-150410

    AUTACs Cancer
    TSPO ligand-3 is a ligand of AUTAC2. AUTAC2 contains an p-fluorobenzylguanine (FBnG) and an synthetic ligand of FKBP (SLF) moiety, which can cause significant silencing of FKBP12 in HeLa cells .
    TSPO ligand-3
  • HY-145514B

    PROTACs FKBP Cancer
    dTAGV-1-NEG TFA is a diastereomer and as a heterobifunctional negative control of dTAGV-1. dTAGV-1-NEG TFA is an FKBP12 F36V-selective degrader .
    dTAGV-1-NEG TFA
  • HY-10218S

    RAD001-d4; SDZ-RAD-d4

    mTOR FKBP Autophagy Apoptosis Cancer
    Everolimus-d4 is the deuterium labeled Everolimus. Everolimus (RAD001) is a Rapamycin derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities[1][2].
    Everolimus-d4
  • HY-129363

    Ligands for Target Protein for PROTAC FKBP Cancer
    AP1867-3-(aminoethoxy), the AP1867 based moiety, is a synthetic ligand for FKBP. AP1867-3-(aminoethoxy) can be used in the synthesis of PROTAC FKBP12 F36V degrader .
    AP1867-3-(aminoethoxy)
  • HY-135250B

    E3 Ligase Ligand-Linker Conjugates Autophagy Apoptosis Cancer
    Thalidomide-4-O-C6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13, a degrader of FKBP12 F36V and BET .
    Thalidomide-4-O-C6-NH2 hydrochloride
  • HY-10218R

    RAD001 (Standard); SDZ-RAD (Standard)

    mTOR FKBP Autophagy Apoptosis Bacterial Cancer
    Everolimus (Standard) is the analytical standard of Everolimus. This product is intended for research and analytical applications. Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .
    Everolimus (Standard)
  • HY-112210
    Shield-1
    5 Publications Verification

    Shld1

    FKBP Others
    Shield-1 (Shld1) is a specific, cell-permeant and high-affinity ligand of FK506-binding protein-12 (FKBP), and reverses the instability by binding to mutated FKBP (mtFKBP), allowing conditional expression of mtFKBP-fused proteins. Shield-1 can stabilize proteins tagged with a mutated FKBP12-derived destabilization domain (DD) .
    Shield-1
  • HY-135250A

    E3 Ligase Ligand-Linker Conjugates Autophagy Apoptosis Cancer
    Thalidomide-4-O-C6-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13 (HY-114421), a degrader of FKBP12 F36V and BET .
    Thalidomide-4-O-C6-NH2 TFA
  • HY-106345

    FKBP Calcium Channel Neurological Disease Inflammation/Immunology
    ILS-920 is a nonimmunosuppressive Rapamycin analog with reduced immunosuppressive activity and potent neuroprotective activity. ILS-920 binds selectively to the immunophilin FKBP52 and to the β1-subunit of L-type voltage-gated calcium channels (VGCC). ILS-920 shows 200-fold selectivity for FKBP52 versus FKBP12 .
    ILS-920
  • HY-169147

    Ligands for E3 Ligase Cancer
    MY-11B is a DCAF1 ligand. MY-11B shows reactivity with DCAF1_C1113. MY-11B blockes YT41R and YT47R-mediated degradation of HA-FKBP12. MY-11B can be used in the synthesis of PROTACs .
    MY-11B
  • HY-172152

    FKBP Calcium Channel Neurological Disease
    MP-010 is a FKBP12 ligand that regulates cytosolic calcium by stabilizing RyR channel activity. MP-010 promotes functional improvement in SOD1 G93A amyotrophic lateral sclerosis (ALS) mice, as evidenced by improved motor coordination, increased integrity of neuromuscular junctions, and significantly enhanced survival of spinal motor neurons. MP-010 can be used for research in the field of neurological diseases .
    MP-010
  • HY-147196

    PROTACs FKBP Cancer
    KB03-SLF (compound 6) is an electrophilic PROTAC degrader that binds to DCAF16 to degrade the nuclear protein FKBP12. KB03-SLF can be used in cancer research . (Pink: Ligand for target protein SLF (HY-114872); Black: Linker (HY-W040168); Blue: Ligand for E3 ligase (HY-169968)).
    KB03-SLF
  • HY-163807

    PROTACs FKBP Cancer
    22-SLF is a PROTAC degrader, that degrades FK506-binding protein 12 (FKBP12) with a DC50 of 0.5 µM in a FBXO22 dependent manner. 22-SLF degrades other endogenous proteins, such as BRD4 and EML4-ALK fusion protein.(Pink: Ligand for target protein SLF (HY-114872); Black: Linker (HY-163821); Blue: Ligand for E3 ligase (HY-163826)) .
    22-SLF
  • HY-10219S1

    Sirolimus-13C,d3; AY-22989-13C,d3

    Isotope-Labeled Compounds mTOR FKBP Autophagy Cancer
    Rapamycin- 13C,d3 (Sirolimus- 13C,d3; AY-22989- 13C,d3) is the 13C and deuterium labeled Rapamycin (HY-10219) .Rapamycin is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant .
    Rapamycin-13C,d3
  • HY-111373
    RapaLink-1
    5+ Cited Publications

    mTOR Autophagy Cancer
    RapaLink-1, the third-generation bivalent mTOR inhibitor, combines Rapamycin (HY-10219) with MLN0128 (HY-13328, a second-generation mTOR kinase inhibitor) by an inert chemical linker. RapaLink-1 shows better efficacy than Rapamycin or mTOR kinase inhibitors (TORKi), potently blocking cancer-derived, activating mutants of mTOR. RapaLink-1 can cross the blood-brain barrier. RapaLink-1 binding to FKBP12 results in targeted and durable inhibition of mTORC1. RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy. Anticancer activity .
    RapaLink-1
  • HY-145712

    FKBP Cancer
    ElteN378 is an inhibitors of FKBP12e. ElteN378 can be used in study Alzheimer disease, Parkinson disease, Amyotrophic Lateral Sclerosis, proliferation disorders and cancer .
    ElteN378
  • HY-13557R

    FKBP Parasite Fungal Antibiotic Infection Neurological Disease Inflammation/Immunology
    Ascomycin (Standard)
  • HY-13557
    Ascomycin
    5+ Cited Publications

    Immunomycin; FR-900520; FK520

    FKBP Parasite Fungal Antibiotic Infection Neurological Disease Inflammation/Immunology
    Ascomycin (Immunomycin; FR-900520; FK520) is an ethyl analog of Tacrolimus (FK506) with strong immunosuppressant properties. Ascomycin is also a macrocyclic polyketide antibiotic with multiple biological activities such as anti-malarial, anti-fungal and anti-spasmodic. Ascomycin prevents graft rejection and has potential for varying skin ailments research .
    Ascomycin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: